Recruiting Real-World Effects of MC4R Agonist Therapy in BBS and Severe Genetic Obesity NCT07674290 Conditions Abnormalities, Multiple, Alstrom Syndrome, Bardet Biedl Syndrome, +25 more Locations University Hospital Essen, Deparment of Pediatrics II — Essen, Germany View Trial Details
Recruiting Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford NCT01793168 Conditions 1p36 Deletion Syndrome, 3-Methylglutaconic Aciduria, Type V, 4p Deletion Syndrome, Non-Wolf-Hirschhorn Syndrome, +698 more Locations Sanford Health — Sioux Falls, South Dakota, United States Online Patient Enrollment System — Sydney, Australia View Trial Details
Recruiting COhort for Bardet-Bield Syndrome and Alström Syndrome for Translational Research Monocentric Interventional Study NCT04461444 Conditions Abnormalities, Multiple, Alstrom Syndrome, Alström Syndrome, +19 more Locations Les Hôpitaux Universitaires de Strasbourg — Strasbourg, France View Trial Details
Completed Setmelanotide (RM-493), Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Participants With Moderate to Severe Obesity NCT03746522 Conditions Abnormalities, Multiple, Alstrom Syndrome, Alström Syndrome (AS), +28 more Locations Wr-McCr, Llc — San Diego, California, United States UMMS Baystate Health; BAYSTATE MEDICAL CENTER; Baystate Children's Specialty Center — Springfield, Massachusetts, United States Columbia University Center — New York, United States M3 Wake Research — Raleigh, North Carolina, United States View more locations Show fewer locations Loading locations... View Trial Details
